title: Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin.
abstract: The fixed dose combination of sitagliptin 50 mg and metformin 850 mg (Janumet ®), is indicated for the treatment of type 2 diabetes mellitus in addition to diet and exercise to improve glycemic control in patients treated with metformin alone.
  
  
  METHODS
  We report a 69-year-old man with type 2 diabetes that developed sudden loss of eyebrows and eyelashes about 4 months after the beginning of Janumet®. Clinical and laboratory findings excluded the presence of systemic or skin diseases able to induce these manifestations, while the Naranjo probability scale documented a possible association between the drug and the adverse drug reaction.
authors.forename: Elena
authors.initials: E
authors.lastname: Succurro
authors.forename: Caterina
authors.initials: C
authors.lastname: Palleria
authors.forename: Mariafrancesca
authors.initials: M
authors.lastname: Ruffo
authors.forename: Raffaele
authors.initials: R
authors.lastname: Serra
authors.forename: Franco
authors.initials: F
authors.lastname: Arturi
authors.affiliation: Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital, Viale Europa - Germaneto, 88100 Catanzaro,. Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Gallelli
mesh_terms: D000368:Aged; D000505:Alopecia / Q000139:chemically induced* / Q000175:diagnosis*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005138:Eyebrows / Q000187:drug effects* / Q000473:pathology; D005140:Eyelashes / Q000187:drug effects* / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000009:adverse effects; D000068900:Sitagliptin Phosphate / Q000008:administration & dosage / Q000009:adverse effects; D000068899:Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D000068899:Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; D008687:Metformin; D000068900:Sitagliptin Phosphate
keywords: Adverse drug reaction; metformin; sitagliptin; type 2 diabetes mellitus